Novozymes has rewarded shareholders with a solid run in recent years, which naturally raises a simple question for anyone looking at the chart today. Is the current share price still in line with the cash flows the business is expected to generate, or has sentiment moved ahead of the underlying economics?
-
Over the past 3 years, Novozymes has delivered a 63.7% return, which puts real pressure on the numbers to show that cash generation can support that kind of share price progress.
-
The group relies on enzyme and biological solutions that often come with long customer relationships and recurring orders, which can help support visibility on future cash flows and the timing of reinvestment needs.
-
If you'd rather focus on earnings, this one's for you. See why Novozymes's 47.5x P/E tells a different valuation story .
The issue now is whether the cash flows implied by Novozymes' current valuation look consistent with what the business can realistically produce over time.
If you are weighing whether Novozymes' 63.7% three year return is properly backed by its cash flows, it can help to cross check that picture against a focused screen of 194 high quality undervalued stocks .
Is Novozymes a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model here is built around Novozymes' ability to keep turning steady operations into hard cash. Over the last twelve months the group produced free cash flow of about €870.7 million, and the model assumes that this cash generation grows rather than shrinks over time as projects already in motion mature and larger customers keep drawing on its enzyme and biological platforms.
Analysts feeding into the DCF expect free cash flow in later years to be higher than today, with the 2 Stage Free Cash Flow to Equity setup tapering that growth as Novozymes becomes a more cash generative but less rapidly expanding operation. When those projected cash flows are discounted back and stacked up against the current share price of DKK481.50, the DCF projections put Novozymes' estimated intrinsic value substantially above the current share price. Find out what Novozymes could be worth using our Discounted Cash Flow (DCF) estimate .
The Novozymes Narrative: What Would Justify Today's Price?
Narratives for Novozymes pick up where the DCF puzzle leaves off and spell out which future paths for growth, margins and earnings would need to play out for the share price to look materially higher or lower than it does today, using scenarios shared on Simply Wall St's Community page. Rather than treating a single multiple or model line as the answer, each narrative lays out the assumptions behind its fair value so you can track them against Novozymes' reported results over time.
Community views on Novozymes are split between investors who see more upside left in the story and others who think expectations are already full.
Bull case: roughly fairly valued
"Strategic build out of commercial and technical presence in high growth emerging markets, combined with a robust innovation pipeline and cross selling synergies from acquisitions such as Feed Enzyme Alliance..."
Discover why this Narrative puts Novozymes at roughly fairly valued .
Bear case: 14% overvalued
"Although emerging markets are delivering double-digit volume growth helped by local labs and commercial teams, intensifying regional competition and potential regulatory hurdles in key countries could slow incremental share gains..."
Explore why this Narrative puts Novozymes at 14% overvalued .
Before acting on Novozymes' valuation, one more lever matters
Price and cash flows tell only part of the story for Novozymes, because the people setting priorities, taking risks and approving capital allocation, plus how they are rewarded, can tilt outcomes in ways the numbers here do not cover. See who runs Novozymes and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NSIS-B.CO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
